The definitive guide to gene editing.
★
Menu
Home Learn News Ask the Atlas
Explore Technologies Diseases Treatments Clinical Trials Companies Scientists Genes Research Institutions
Beyond medicine Agriculture Ethics Investing World map
Learn & Tools Start here Glossary A–Z Compare technologies Timeline Lists & Rankings AI Agents ★ Saved API
About About us Methodology Data Sources Editorial Policy Contact Disclaimers

🧭 Guided View
New to genetics? We explain every term as you browse, in plain English. Same pages, with the help built in.

⚡ Expert View
You already know the biology. Just the content — clean and compact, no extra explanations. This is the default view.

Interface language
Light mode

Nasdaq: CRBU · Berkeley, California

Caribou Biosciences

Co-founded by Jennifer Doudna, using hybrid RNA-DNA guides intended to make editing fussier about where it cuts.

Phase I Cell therapy

Pipeline

Where each disclosed programme stands. Stages come from the company's own disclosures on the date shown.

ProgrammeDiseaseTechnologyStage
CB-010 B-cell lymphoma; autoimmune Cas12a chRDNA DiscoveryPreclinicalPhase IPhase IIPhase IIIApproved
CB-011 Multiple myeloma Cas12a chRDNA DiscoveryPreclinicalPhase IPhase IIPhase IIIApproved

Pipeline as recorded in the Atlas on Aug 25, 2026. Companies revise pipelines frequently — verify against the company's own materials and regulatory filings.

In one paragraph

Caribou's distinguishing idea is the guide itself: instead of an all-RNA guide, it uses a hybrid of RNA and DNA, which the company says makes the editing machinery more particular about matching its target exactly. It applies this to off-the-shelf CAR-T cell therapies for blood cancers and autoimmune disease.

Caribou Biosciences was founded in 2011 by Jennifer Doudna, Rachel Haurwitz, Martin Jinek and James Berger. Its chRDNA platform uses hybrid CRISPR RNA-DNA guides with Cas12a, reported to reduce off-target editing. Lead programmes are allogeneic CAR-T candidates including CB-010 (anti-CD19) and CB-011 (anti-BCMA).

Sources

Not investment advice This profile is educational information compiled from public disclosures. It is not a recommendation to buy, sell or hold any security, and it is not a view on the company's prospects. Biotechnology is highly speculative and most clinical programmes fail. Full disclaimers →
Written by The CRISPR Atlas editorial team Last updated Aug 25, 2026

Connected in the Atlas

Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.

Technologies

CRISPR-Cas12

Diseases

Leukemia and Lymphoma

Treatments

CB-010

Clinical Trials

A Study of CB-010 in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Scientists

Jennifer Doudna